AMRX — Amneal Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1723128 ·
Last close
$21.12
Market Cap
$7.36B
52W High
$22.07
52W Low
$11.39
ADV30
3,879,002
Next earnings
2026-11-03
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 796,197,000 334,508,000 145,980,000 57,662,000 3,776,348,000 127,637,000 3,743,324,000
Mar 2026 722,519,000 320,113,000 148,269,000 62,256,000 3,540,218,000 197,656,000 3,586,187,000
Dec 2025 814,319,000 297,190,000 114,503,000 35,076,000 3,678,280,000 282,029,000 3,749,609,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$180,627,000
Investing CF
$-662,139,000
Financing CF
$425,371,000
CapEx
$-241,807,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.42
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-436,782,000
Inventory
$707,956,000
Receivables
$1,144,498,000
ST Investments
—
EBIT TTM
$445,012,000
Pretax Income TTM
$221,458,000
Interest Exp TTM
$223,554,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,195,718,912
EBITDA
$726,766,016
Free Cash Flow
$-45,125,624
Enterprise Value
$10,679,200,768
Total Cash
$162,211,008
Total Debt
$3,282,895,104
Shares Out
348,412,726
Trailing EPS
$0.40
Book Value
$1.52
ROE
70.0%
ROA
7.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,018,760,000 397,914,000 72,057,000 3,678,280,000 3,749,609,000 -70,794,000 339,992,000
Dec 2024 2,793,957,000 348,373,000 -116,886,000 3,501,445,000 3,610,957,000 -109,267,000 295,099,000
Dec 2023 2,393,607,000 238,747,000 -83,993,000 3,472,569,000 3,452,558,000 19,781,000 345,577,000
Dec 2022 2,212,304,000 188,922,000 -129,986,000 3,799,341,000 3,615,362,000 298,421,000 65,100,000

TTM Snapshot

Revenues TTM
$3,117,548,000
NetIncome TTM
$157,363,000
OpCashFlow TTM
—
Assets (Latest)
$3,776,348,000
Forward EPS
$1.23

Max Pain — expiry 2027-03-19

max pain strike: $20.00 · spot: $21.88 · call oi: 2,475 · put oi: 2,025
Expected Move to 2027-03-19: ±$6.25 (28.56%) — implied range $15.63 – $28.13 · ATM straddle on $22.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CYTK CYTOKINETICS INC $7.20B $51.65 —
ABVX Abivax S.A. $7.16B $82.10 —
AXSM Axsome Therapeutics, Inc. $7.15B $135.95 —
ALKS Alkermes plc. $7.64B $45.45 —
CORT CORCEPT THERAPEUTICS INC $7.67B $70.07 —

News headlines (Yahoo Finance, 1h cache)

Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
2026-11-18 16:34 · Yahoo
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
2026-11-18 15:35 · Yahoo
Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
2026-11-17 21:05 · Yahoo
3 Insider Backed Growth Stocks With At Least 40% Earnings Growth
2026-11-17 18:10 · Yahoo
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
2026-11-17 15:11 · Yahoo
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
2026-11-16 16:13 · Yahoo
QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?
2026-11-13 17:16 · Yahoo
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
2026-11-13 15:41 · Yahoo
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
2026-11-13 13:20 · Yahoo
ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns
2026-11-13 11:22 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.